CSIMarket
 
Aura Biosciences Inc   (AURA)
Other Ticker:  
 
 
Price: $7.0900 $-0.11 -1.528%
Day's High: $7.27 Week Perf: -11.15 %
Day's Low: $ 6.97 30 Day Perf: -18.51 %
Volume (M): 304 52 Wk High: $ 13.50
Volume (M$): $ 2,154 52 Wk Avg: $9.61
Open: $7.15 52 Wk Low: $5.99



 Market Capitalization (Millions $) 271
 Shares Outstanding (Millions) 38
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) -66
 Capital Exp. (TTM) (Millions $) 0

Aura Biosciences Inc
Aura Biosciences Inc is a clinical-stage biotechnology company that focuses on developing and commercializing innovative cancer therapies. The company specializes in developing targeted therapies called viral nanoparticles, which are designed to deliver lethal doses of radiation directly to cancer cells while sparing healthy tissues. These nanoparticles are engineered to selectively bind to cancer cells and are activated by light, resulting in the destruction of the tumor.

One of the company's lead candidates is AU-011, which is being investigated as a treatment for choroidal melanoma, a rare and aggressive eye cancer. AU-011 has shown promising clinical results in early-stage studies and is currently being evaluated in advanced clinical trials.

Aura Biosciences Inc aims to provide a more effective and targeted treatment approach for cancer patients, reducing side effects and improving the quality of life. By harnessing the power of viral nanoparticles, the company is advancing the field of precision medicine and working towards better outcomes for patients with various types of cancer.


   Company Address: 80 Guest Street Boston 2135 MA
   Company Phone Number: 500-8864   Stock Exchange / Ticker: NASDAQ AURA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Aura Biosciences Takes Aim at Early-Stage Choroidal Melanoma with Groundbreaking Phase 3 Trial of Bel-sar

Published Thu, Dec 7 2023 1:00 PM UTC

Aura Biosciences Advances First-Line Treatment for Early-Stage Choroidal Melanoma with Bel-sar in Phase 3 Trial
Boston-based biotechnology company, Aura Biosciences Inc. (NASDAQ: AURA), has made a significant breakthrough in the field of oncology with the initiation of its Phase 3 CoMpass trial. The trial aims to evaluate the safety and efficacy of Belzupacap Sarotalocan...

Aura Biosciences Inc

Aura Biosciences Inc. Emerges as a Powerhouse in the Biotechnology & Pharmaceuticals Sector: Unveiling Stellar Fiscal Period Results



Aura Biosciences Inc, a clinical-stage biotechnology company, recently reported its financial results for the third quarter of 2023. While the company made progress across its portfolio, investors have expressed concerns over the significant drop in share value and the absence of revenue. This article will analyze the implications of these results and discuss their potential impact on Aura Biosciences Inc in the future.
Drop in Share Value:
Over the past week, Aura Biosciences Inc shares have experienced a significant decline of -30.09%. This slump brings the year-to-date performance to -27.93%, raising concerns among investors about the company's stability and future prospects. Additionally, even though the shares currently trade 28.4% above the 52-week low, the recent downward trend is a cause for further concern.

Aura Biosciences Inc

Aura Biosciences Inc Sees Soaring Revenue, but Faces Growing Operating Deficit - What Does This Mean for the Company's Future?



Aura Biosciences Inc, a leading biotechnology and pharmaceutical company, has recently released its financial results for the fiscal period between April and June 2023. These results indicate a consistent increase in revenue, but also highlight a growing operating deficit. This article aims to interpret the financials and shed light on the overall performance and prospects of the company.
Financial Results Overview:
The shareholders of Aura Biosciences Inc had high expectations for the revenue throughout the fiscal cycle of April to June 2023. However, the company reported an operating deficit of $-20.276 million, which raises concerns about their financial stability for the given period. To put this in perspective, the operating deficit during the same quarter in 2022 was $-13.816 million. This signifies a widening deficit, necessitating a closer examination of the company's policies and strategies.

Aura Biosciences Inc

Aura Biosciences Inc. Reports Second Consecutive Year of Operating Shortfall

As the January to March reporting cycle for 2023 resumes, many businesses in the Biotechnology & Pharmaceuticals sector have reported their respective numbers. One company in this sector, AURA Biosciences Inc., has disclosed an operating shortfall of $-19.444 million for the first financial quarter of 2023. This news is important to contextualize the current state of the company.
The operating shortfall for the first quarter of 2023 can be correlated with the operating shortfall for the first quarter of 2022, which was $-12.811 million. This suggests that AURA Biosciences Inc. is experiencing a consistent pattern of financial difficulty.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com